Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

IMMP Relative to the S&P 500

IMMP Relative to the Sector

Seasonal Chart Analysis

Analysis of the Immutep Limited (NASD:IMMP) seasonal charts above shows that a Buy Date of March 14 and a Sell Date of June 2 has resulted in a geometric average return of 11.64% above the benchmark rate of the S&P 500 Total Return Index over the past 12 years. This seasonal timeframe has shown positive results compared to the benchmark in 9 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 12 years by an average of 36.01% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its?main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

To download IMMP seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: IMMP